Retrieve available abstracts of 152 articles: HTML format
Single Articles
August 2025
HOSHINA Y, Smith TL, Mstat AD, Wong KH, et al An updated, comprehensive meta-analysis of the treatment of anti-NMDAR
encephalitis: Analysis, equipoise, and the urgent need for evidence over
anecdote.
J Neuroimmunol. 2025;405:578651. PubMedAbstract available
MIYAKE S, Katsura Y, Baba M, Tomizawa-Shinohara H, et al Anti-IL-6R antibody treatment changes microglial phenotype in AQP4
peptide-immunized mice, leading to suppression of myelitis severity.
J Neuroimmunol. 2025;405:578644. PubMedAbstract available
July 2025
INOUE Y, Fujii T, Kashu KY, Watanabe M, et al Associations between serum levels of alpha-calcitonin gene-related peptide and
clinical features of neuromyelitis optica spectrum disorders.
J Neuroimmunol. 2025;404:578615. PubMedAbstract available
SANDWEISS AJ, Rosen J, Aduru C, Chandrasekar A, et al MOGAD optic neuritis after mild head/orbital trauma in six children.
J Neuroimmunol. 2025;404:578605. PubMedAbstract available
JAHANSOOZ JR, Kameoka AM, Shibuya J, Abramowitz J, et al Recurrent anti-NMDA receptor encephalitis in first-trimester pregnancy with
initially antibody-negative CSF.
J Neuroimmunol. 2025;404:578602. PubMedAbstract available
June 2025
WELSH NC, DiSano KD, Pike SC, Linzey M, et al Network analysis of intrathecally synthesized proteins to unravel mechanisms of
disease course in multiple sclerosis.
J Neuroimmunol. 2025;406:578678. PubMedAbstract available
NIBBER A, Wills B, Pettingill P, Fox H, et al Evolution and significance of neuronal surface autoantibodies after Japanese
encephalitis.
J Neuroimmunol. 2025;406:578671. PubMedAbstract available
WON J, Kim J, Qiao F, Singh AK, et al Therapeutic potential of S-nitrosoglutathione reductase inhibitor in B
cell-driven experimental autoimmune encephalomyelitis.
J Neuroimmunol. 2025;406:578673. PubMedAbstract available
NASEER MA, Hegazy M, El-Mehdawy KM, Ashraf H, et al Serum levels of tumor necrosis factor and TNFRSF1A gene polymorphisms in Egyptian
multiple sclerosis patients: the influence on susceptibility and severity.
J Neuroimmunol. 2025;406:578672. PubMedAbstract available
PEREIRA DA, Mariano M, Marcon N, Maia MM, et al A rare neuroendocrine presentation in pediatric anti-glutamic acid decarboxylase
autoimmunity: Case report and literature review.
J Neuroimmunol. 2025;406:578670. PubMedAbstract available
CAKAN M, Demirel E, Cimen B, Ozen NPA, et al Comparison of clinical features of aquaporin-4 positive neuromyelitis optica
spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein associated
disorder (MOGAD), and double seronegative NMOSD - A single center experience.
J Neuroimmunol. 2025;403:578591. PubMedAbstract available
ABBOUD H, Steingo B, Vargas D, Patel J, et al Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis
optica spectrum disorder after rituximab treatment: A case series.
J Neuroimmunol. 2025;403:578585. PubMedAbstract available
ZIVOTIC I, Kolic I, Stefanovic M, Stefanovic NM, et al Association of TGFB1 and IFNB1 expression levels in peripheral blood mononuclear
cells with multiple sclerosis with respect to proximal rs1800469 and rs2275888
eQTLs.
J Neuroimmunol. 2025;406:578666. PubMedAbstract available
JOHNSON CB, Fehmi J, Rinaldi S The immunology and neuropathology of the autoimmune nodopathies.
J Neuroimmunol. 2025;406:578665. PubMedAbstract available
SAGHARICHI M, Aalipour MA, Eghbal E, Javandoust Gharehbagh F, et al Autoimmune encephalitis and delayed diagnosis in common variable
immunodeficiency: A case report and review of literature.
J Neuroimmunol. 2025;406:578662. PubMedAbstract available
May 2025
WEIGEL J, Appeltshauser L, Sommer C, Doppler K, et al Proprioceptive endings at muscle spindles as a possible target of autoantibodies.
J Neuroimmunol. 2025;405:578648. PubMedAbstract available
YAO ZY Reflections on the influence of seasonal and environmental factors in myasthenia
gravis.
J Neuroimmunol. 2025;405:578645. PubMed
MAKHARIA A, Agarwal A, Garg D, Garg A, et al The dilemma of demyelination: A case of Schilder's disease with insights from
literature.
J Neuroimmunol. 2025;402:578584. PubMedAbstract available
WANG Y, Huan X, Song J, Zhu X, et al Clinical outcome and peripheral CD4(+) T profile in impending myasthenic crisis:
A prospective cohort study.
J Neuroimmunol. 2025;402:578572. PubMedAbstract available
April 2025
DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al Corrigendum to "Novel model of multiple sclerosis induced by EBV-like virus
generate a unique B cell population" [Journal of Neuroimmunology volume 394
(2024) 578408].
J Neuroimmunol. 2025;404:578625. PubMed
ONISHI Y, Uzawa A, Yasuda M, Akamine H, et al Elevated serum levels of IL-10 family and IL-12 family cytokines in myasthenia
gravis.
J Neuroimmunol. 2025;404:578621. PubMedAbstract available
MASI F, Al Qudsi S, Visigalli D, Zardini E, et al Oligoclonal IgM band patterns in multiple sclerosis: A two-center study.
J Neuroimmunol. 2025;404:578622. PubMedAbstract available
NAGAPPA M, Mondal S, Rajeevan S, Pradeepkumar B, et al Exploring the role of altered oxi-inflammasome activity in the immunobiology of
inflammatory neuropathies.
J Neuroimmunol. 2025;401:578556. PubMedAbstract available
LI Q, Liu B, Guan Y, Wang Y, et al Double filtration plasmapheresis in autoimmune gastritis with subacute combined
degeneration of the spinal cord: A case report.
J Neuroimmunol. 2025;403:578618. PubMedAbstract available
ZHARIKOV Y, Shitova A, Melnikova P, Voloshin I, et al Autoantibody-mediated disorders of the central and peripheral nervous system:
Overview Infection.
J Neuroimmunol. 2025;403:578616. PubMedAbstract available
EL MAHDAOUI S, Husted SR, Hansen MB, Cobanovic S, et al Corrigendum to "Cerebrospinal fluid soluble CD27 is associated with CD8+ T cells,
B cells and biomarkers of B cell activity in relapsing-remitting multiple
sclerosis" [Journal of neuroimmunology vol. 381 (2023): 578128].
J Neuroimmunol. 2025;403:578607. PubMed
PETROU P, Kassis I, Levi Y, Yaghmour N, et al Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients
treated with repeated administrations of autologous mesenchymal stem cells
(MSC-NG01).
J Neuroimmunol. 2025;403:578613. PubMedAbstract available
TRAN GT, Bedi S, Rakesh P, Verma ND, et al Autoantigen and IL-2 activated CD4(+)CD25(+)T regulatory cells are induced to
express CD8 and are autoantigen specific in inhibiting experimental autoimmune
encephalomyelitis.
J Neuroimmunol. 2025;404:578611. PubMedAbstract available
ZHANG Z, Wu J, Xu D, Zhao S, et al Clinical characteristics and immunotherapy efficacy in autoimmune-associated
benign epilepsy with centrotemporal spikes: A prospective cohort study.
J Neuroimmunol. 2025;404:578603. PubMedAbstract available
MARQUES RF, Pedrosa DA, Talim N, Lemos JC, et al Relapsing-remitting multiple sclerosis as a potential consequence of thalidomide
treatment: A case report.
J Neuroimmunol. 2025;404:578606. PubMedAbstract available
STAYKOVA M, Bruestle A Nitric oxide and experimental autoimmune encephalomyelitis review.
J Neuroimmunol. 2025;404:578586. PubMedAbstract available
March 2025
WANG Z, Du X, Wang Q, Zhang Y, et al Ofatumumab for the treatment of COVID-19-associated autoimmune encephalitis: A
case report.
J Neuroimmunol. 2025;403:578590. PubMedAbstract available
ZEYDAN B, Neyal N, Nathoo N, Rangachari M, et al Effects of androgen modifying therapies on disease activity in older men with
multiple sclerosis.
J Neuroimmunol. 2025;403:578589. PubMedAbstract available
CHUANG TY, LaBarre BA, Corbali O, Healy BC, et al Endocrine disrupting chemicals in early MS disease activity.
J Neuroimmunol. 2025;400:578546. PubMedAbstract available
February 2025
KHEDR EM, Hassan MM, Ezzeldeen MY, El-Kady MS, et al Motor symptoms at onset and manual dexterity predict cognitive impairment in
drug-naive individuals with multiple sclerosis.
J Neuroimmunol. 2025;401:578571. PubMedAbstract available
SHAHBAKHSH M, Jalousian F, Hosseini SH, Naser Moghadasi A, et al Toxocara canis-originated recombinant C-type lectin improves the disability
scores of experimental autoimmune encephalomyelitis in murine in vivo models.
J Neuroimmunol. 2025;402:578569. PubMedAbstract available
KUO PC, Zhao Z, Scofield BA, Paraiso HC, et al Benzoylacetonitrile as a novel anti-inflammatory compound on attenuating
microglia and encephalitogenic T cell activation in experimental autoimmune
encephalomyelitis.
J Neuroimmunol. 2025;401:578557. PubMedAbstract available
HE D, Zhou Y, Zhang Y, Zhang J, et al Response of refractory residual ocular symptoms to efgartigimod in generalized
myasthenia gravis: A real-world case series.
J Neuroimmunol. 2025;401:578558. PubMedAbstract available
GHOSH S, Bhaskar R, Singh KK, Sinha JK, et al Immunotherapy challenges and potential role of unclassified antibodies in complex
autoimmune encephalitis.
J Neuroimmunol. 2025;401:578555. PubMed
LIU Y, Sun H, Xu Y, Xuan B, et al Identification and characteristics of a novel CD8alphaalpha T cell subset in a refractory
myasthenia gravis patient.
J Neuroimmunol. 2025;400:578551. PubMedAbstract available
ZHANG M, Zhu X, Yu L, Fang Z, et al Pediatric anti-CaValpha2delta autoimmune encephalitis: A case report and literature
review.
J Neuroimmunol. 2025;401:578550. PubMedAbstract available
YAN Z, Yang X, Lin B, Zhu Q, et al Brain network alteration was associated with 'no evidence of disease activity'
status in patients with relapsing-remitting multiple sclerosis.
J Neuroimmunol. 2025;400:578549. PubMedAbstract available
CULINA S, Commere PH, Turc E, Jouy A, et al MicroRNA signatures of CD4(+) T cell subsets in healthy and multiple sclerosis
subjects determined by small RNA-sequencing.
J Neuroimmunol. 2025;401:578531. PubMedAbstract available
January 2025
RANDHAWA G, Mobarakabadi M, D'Mello C, Morch MT, et al Targeting extracellular matrix components to attenuate microglia
neuroinflammation: A study of fibulin-2 and CSPGs in a model of multiple
sclerosis.
J Neuroimmunol. 2025;400:578533. PubMedAbstract available
FALK KK, Cabrera LA, Junker R, Leypoldt F, et al Serum NfL predicts outcome and secondary autoimmunity in herpes-simplex
encephalitis.
J Neuroimmunol. 2025;400:578528. PubMedAbstract available
ETEMADIFAR M, Aghili A, Shojaei S, Alaei SA, et al Balo concentric sclerosis, an emerging variant of multiple sclerosis: A
case-series and literature review.
J Neuroimmunol. 2025;400:578527. PubMedAbstract available
LI Y, Chen P, Huang X, Huang H, et al Corrigendum to "Pathogenic Th17 cells are a potential therapeutic target for
tacrolimus in AChR-myasthenia gravis patients" [Journal of Neuroimmunology. 2024
Nov 15:396:578464].
J Neuroimmunol. 2025 Jan 16:578526. doi: 10.1016/j.jneuroim.2025.578526. PubMed
VORASOOT N, Halfdanarson TR, Madigan NN, Dubey D, et al Pre-existing Lambert-Eaton Myasthenic Syndrome and Scleroderma in a Patient with
Neuroendocrine Carcinoma Undergoing Immune Checkpoint Inhibitor Cancer
Immunotherapy.
J Neuroimmunol. 2025;398:578485. PubMedAbstract available
GULEC B, Everest E, Uygunoglu U Letter to the Editor Regarding "Spinocerebellar ataxia masquerading as multiple
sclerosis, a case report".
J Neuroimmunol. 2025;399:578523. PubMed
FALSO S, Zara P, Marini S, Puci M, et al Seasonal variation in myasthenia gravis incidence.
J Neuroimmunol. 2025;399:578524. PubMedAbstract available
December 2024
GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al Corrigendum to "Elevated frequencies of activated memory B cells in multiple
sclerosis are reset to healthy control levels are B cell depletion with
Ocrelizumab" [J. Neuroimmunol. 339:578502 (2024)].
J Neuroimmunol. 2024;399:578519. PubMed
ITOH C, Swart G, St Louis E, Gandhi M, et al IgLON5 autoimmunity secondary to immune checkpoint inhibitor.
J Neuroimmunol. 2024;399:578516. PubMedAbstract available
HERNANDEZ RUIZ JJ, Romero Malacara AMC, Lopez Mota LA, Perez Guzman MJ, et al Therapeutic development towards T follicular helper cells as a molecular target
in myasthenia gravis disease.
J Neuroimmunol. 2024;399:578503. PubMedAbstract available
LIANG Y, Huang J, Zhang X, Xu F, et al Quantitative assessment of thalamic damage and serum neurofilament light chain in
relapsing-remitting multiple sclerosis.
J Neuroimmunol. 2024;399:578504. PubMedAbstract available
GILLIGAN M, O'Donnell L, Westbrook A, Tubridy N, et al A complex and severe encephalitis associated with four co-existing neuronal
cell-surface autoantibodies.
J Neuroimmunol. 2024;399:578501. PubMedAbstract available
GURSKI CJ, Hajiyeva Z, Veltri AJ, Fenton K, et al Elevated frequencies of activated memory B cells in multiple sclerosis are reset
to healthy control levels after B cell depletion with Ocrelizumab.
J Neuroimmunol. 2024;399:578502. PubMedAbstract available
November 2024
OZKOSAR A, Oktelik FB, Gelmez MY, Ozturk Erden S, et al Retinoic acid modulates peripheral blood helper innate lymphoid cell composition
in vitro in patients with multiple sclerosis.
J Neuroimmunol. 2024;398:578489. PubMedAbstract available
KIM S, Lee S, Chung YH, Ju H, et al Myelin oligodendrocyte glycoprotein antibody-associated disease with
histopathologic features of primary CNS angiitis without demyelination: Case
report and literature review.
J Neuroimmunol. 2024;396:578467. PubMedAbstract available
LAI R, Wu Z, Wang H, Feng L, et al Ofatumumab treatment for severe refractory anti-NMDAR encephalitis: A case
series.
J Neuroimmunol. 2024;396:578458. PubMedAbstract available
October 2024
FAN Z, Li J, Zhang Y, Kang J, et al Kidney injury: An overlooked manifestation in autoimmune encephalitis.
J Neuroimmunol. 2024;397:578472. PubMedAbstract available
YASUDA M, Uzawa A, Kuwabara S, Suzuki S, et al Corrigendum to "Clinical features and outcomes of patients with muscle-specific
kinase antibody-positive myasthenia gravis in Japan" [Journal of Neuroimmunology
385 (2023) 578241].
J Neuroimmunol. 2024;397:578465. PubMed
CHENG X, Cui C, Shen S, Li Z, et al Probiotics-regulated lithocholic acid suppressed B-cell differentiation in
neuromyelitis optica spectrum disorder.
J Neuroimmunol. 2024;395:578422. PubMedAbstract available
HONG Y, Gao L, Huang SQ, Liu S, et al Efgartigimod as a fast-acting add-on therapy in manifest and impending myasthenic
crisis: A single-center case series.
J Neuroimmunol. 2024;395:578431. PubMedAbstract available
LI Y, Chen P, Huang X, Huang H, et al Pathogenic Th17 cells are a potential therapeutic target for tacrolimus in
AChR-myasthenia gravis patients.
J Neuroimmunol. 2024;396:578464. PubMedAbstract available
September 2024
LIU Y, Yang CL, Zhao XL, Zhao YJ, et al Characteristics of anti-contactin1 antibody positive autoimmune nodopathies
combined with membranous nephropathy.
J Neuroimmunol. 2024;396:578460. PubMedAbstract available
BAI G, Bai Y, Guan H, Ren H, et al A case report of lymphoproliferative disease in brain following therapies with
mycophenolate Mofetil and Fingolimod and literature review.
J Neuroimmunol. 2024;394:578410. PubMedAbstract available
YASUDA M, Uzawa A, Onishi Y, Handa H, et al Elevated serum levels of C-terminal agrin fragment in acetylcholine receptor
antibody-positive myasthenia gravis.
J Neuroimmunol. 2024;396:578455. PubMedAbstract available
BAXTER L, Hopkins S, O'Connor KC, Pham MC, et al Fluorescence-detection size-exclusion chromatography specifically detects
autoantibodies targeting the ganglionic acetylcholine receptor in patients with
autoimmune autonomic ganglionopathy.
J Neuroimmunol. 2024;396:578454. PubMedAbstract available
HUANG YF, Briggs CM, Gokhale S, Punga AR, et al Elevated C1s/C1-INH in serum and plasma of myasthenia gravis patients.
J Neuroimmunol. 2024;396:578447. PubMedAbstract available
SAMIM MM, Mandal R, Joy J, Dhar D, et al Spectrum of Auto-antibodies in NMO and MOG Associated CNS Demyelination- The
SANMAD Study.
J Neuroimmunol. 2024;396:578446. PubMedAbstract available
XU Y, Wei Y, Shi Z, Yin F, et al Multimodal magnetic resonance longitudinal study on the deep gray matter in
multiple sclerosis patients with teriflunomide.
J Neuroimmunol. 2024;396:578445. PubMedAbstract available
August 2024
ABOSEIF A, Amin M, Macaron G, Ontaneda D, et al Discordance of reported multiple sclerosis clinical course amongst patients and
providers.
J Neuroimmunol. 2024;395:578443. PubMedAbstract available
BILEK F, Ercan Z, Deniz G, Ozgul S, et al High-intensity intermittent exercise increases serum levels of chitinase 3-like
protein-1 and matrix metalloproteinase-9 in persons with multiple sclerosis.
J Neuroimmunol. 2024;395:578434. PubMedAbstract available
CHEN P, Chen J, Huang H, Liu W, et al Conventional dendritic cells are more activated in the hyperplastic Thymus of
myasthenia gravis patients.
J Neuroimmunol. 2024;395:578441. PubMedAbstract available
WRIGHT MA, Guasp M, Lachner C, Day GS, et al Authors' response to letter to the editor: Electroconvulsive therapy in
N-methyl-d-aspartate receptor encephalitis.
J Neuroimmunol. 2024;393:578405. PubMed
KRIEGER S, Zarif M, Bumstead B, Buhse M, et al Evaluating the effect of dimethyl fumarate on subclinical biomarkers in a
real-world patient cohort.
J Neuroimmunol. 2024;393:578397. PubMedAbstract available
SHARMA M, Pal P, Gupta SK, Potdar MB, et al Microglial-mediated immune mechanisms in autoimmune uveitis: Elucidating
pathogenic pathways and targeted therapeutics.
J Neuroimmunol. 2024;395:578433. PubMedAbstract available
LEHIKOINEN J, Strandin T, Parantainen J, Nurmi K, et al Fibrinolysis associated proteins and lipopolysaccharide bioactivity in plasma and
cerebrospinal fluid in multiple sclerosis.
J Neuroimmunol. 2024;395:578432. PubMedAbstract available
YARIMI JM, Sandweiss AJ, Salazar KP, Massrey C, et al IT-DEX and B cell depletion in a child with anti-GAD 65 autoimmune encephalitis
presenting as NORSE: A case report.
J Neuroimmunol. 2024;395:578430. PubMedAbstract available
ETEMADIFAR M, Alaei SA, Sedaghat N, Ghandehari AH, et al TEMPORARY REMOVAL: Pure spinal multiple sclerosis: A case series of a possible
new entity.
J Neuroimmunol. 2024 Aug 8:578429. doi: 10.1016/j.jneuroim.2024.578429. PubMed
TORTOSA-CARRERES J, Cubas-Nunez L, Piqueras M, Castillo-Villalba J, et al Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple
sclerosis patients: Could it serve as a valuable marker in clinical practice?
J Neuroimmunol. 2024;394:578428. PubMedAbstract available
July 2024
LI YJ, Zhang XY, Zhang WJ, Han YL, et al Proteomics analysis of immune response-related proteins in Guillain-Barre
Syndrome (GBS) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
J Neuroimmunol. 2024;394:578423. PubMedAbstract available
WUERCH EC, Mirzaei R, Yong VW Niacin produces an inconsistent treatment response in the EAE model of multiple
sclerosis.
J Neuroimmunol. 2024;394:578421. PubMedAbstract available
DEFFENBAUGH JL, Jung KJ, Murphy SP, Liu Y, et al Novel model of multiple sclerosis induced by EBV-like virus generates a unique B
cell population.
J Neuroimmunol. 2024;394:578408. PubMedAbstract available
YOKOTE H, Miyazaki Y, Fujimori J, Nishida Y, et al Characterization of Japanese multiple sclerosis patients with progression
independent of relapse activity: A 2-year multicenter cohort study.
J Neuroimmunol. 2024;394:578407. PubMedAbstract available
PEGAT A, Chanson JB, Lozeron P, Joubert B, et al Identification of rare variants in the FBXO38 gene of patients with chronic
inflammatory demyelinating polyradiculoneuropathy.
J Neuroimmunol. 2024;392:578381. PubMedAbstract available
WRIGHT MA, Guasp M, Lachner C, Day GS, et al Electroconvulsive therapy in N-methyl-d-aspartate receptor encephalitis: A
retrospective cohort and scoping review of literature.
J Neuroimmunol. 2024;392:578369. PubMedAbstract available
FONSECA A, Santos E, Taipa R Balo concentric sclerosis: Literature review and report of two cases.
J Neuroimmunol. 2024;392:578370. PubMedAbstract available
June 2024
LI Y, Yi JS, Guptill JT, Juel VC, et al Immune dysregulation in chronic inflammatory demyelinating polyneuropathy.
J Neuroimmunol. 2024;391:578360. PubMedAbstract available
RECHTMAN A, Zveik O, Haham N, Brill L, et al A protective effect of lower MHC-II expression in MOGAD.
J Neuroimmunol. 2024;391:578351. PubMedAbstract available
WHEELER D, Bezih M, Lannen N Spinocerebellar ataxia masquerading as multiple sclerosis, a case report.
J Neuroimmunol. 2024;393:578385. PubMed
YONG HYF, Batty NJ, Tottenham I, Koch M, et al Soluble adhesion molecules: Cognitive worsening biomarkers in primary progressive
multiple sclerosis?
J Neuroimmunol. 2024;393:578384. PubMed
May 2024
SRIRAM S, Kim KW, Ljunggren-Rose A Targeted DeSUMOylation as a therapeutic strategy for multiple sclerosis.
J Neuroimmunol. 2024;392:578371. PubMedAbstract available
GELIBTER S, Saraceno L, Pirro F, Susani EL, et al As time goes by: Treatment challenges in elderly people with multiple sclerosis.
J Neuroimmunol. 2024;391:578368. PubMedAbstract available
CARVER JJ, Pugh BA, Lau KM, Didonna A, et al Lipid metabolism is dysregulated in endocrine glands upon autoimmune
demyelination.
J Neuroimmunol. 2024;391:578366. PubMedAbstract available
April 2024
LI S, Sun D, Wang R, Du Q, et al Causal association between multiple sclerosis and severe COVID-19: A
bidirectional Mendelian randomization study.
J Neuroimmunol. 2024;391:578352. PubMed
DAMMAN S, Sukpornchairak P, Ahituv A, Chen A, et al Unilateral cortical autoimmune encephalitis: A case series and comparison to
late-onset Rasmussen's encephalitis.
J Neuroimmunol. 2024;391:578350. PubMedAbstract available
MIN YG, Ju W, Sung JJ Superior oblique palsy as the initial manifestation of anti-contactin-1 IgG4
autoimmune nodopathy: A case report.
J Neuroimmunol. 2024;391:578348. PubMedAbstract available
LI V, Binder MD, Purcell AW, Kilpatrick TJ, et al Antigen-specific immunotherapy via delivery of tolerogenic dendritic cells for
multiple sclerosis.
J Neuroimmunol. 2024;390:578347. PubMedAbstract available
MUNZ C Altered EBV specific immune control in multiple sclerosis.
J Neuroimmunol. 2024;390:578343. PubMedAbstract available
March 2024
LUO W, Wang X, Kong L, Chen H, et al Clinical features and prognosis of Tibetan patients with neuromyelitis optica
spectrum disorder are different from those of Han Chinese patients.
J Neuroimmunol. 2024;388:578263. PubMedAbstract available
KATSU M, Sekine-Tanaka M, Tanaka M, Horai Y, et al Inhibition of repulsive guidance molecule-a ameliorates compromised blood-spinal
cord barrier integrity associated with neuromyelitis optica in rats.
J Neuroimmunol. 2024;388:578297. PubMedAbstract available
HAHAM N, Zveik O, Rechtman A, Brill L, et al Altered immune co-inhibitory receptor expression and correlation of LAG-3
expression to disease severity in NMOSD.
J Neuroimmunol. 2024;388:578289. PubMedAbstract available
DE ALMEIDA GMR, de Araujo RS, Castrillo BB, Silva GD, et al Therapeutic plasma exchange for neuromyelitis optica attacks: Evidence and
challenges from a real-world cohort from Brazil.
J Neuroimmunol. 2024;388:578295. PubMedAbstract available
CHANG EH, Hardy TA Peripheral oedema as an adverse effect of treatment of secondary progressive
multiple sclerosis with siponimod: A case series.
J Neuroimmunol. 2024;389:578330. PubMedAbstract available
FOGEL A, Olcer M, Goel A, Feng X, et al Novel biomarkers and interferon signature in secondary progressive multiple
sclerosis.
J Neuroimmunol. 2024;389:578328. PubMedAbstract available
February 2024
KMEZIC I, Press R, Glenewinkel H, Doppler K, et al Low-dose rituximab treatment in a patient with anti-neurofascin-155 IgG4
autoimmune nodopathy.
J Neuroimmunol. 2024;389:578326. PubMedAbstract available
SRIWASTAVA S, Elkhooly M, Amatya S, Shrestha K, et al Recent advances in the treatment of primary and secondary progressive Multiple
Sclerosis.
J Neuroimmunol. 2024;390:578315. PubMedAbstract available
ZHANG C, Liu R, Gao B, Li T, et al Efficacy and safety of low- and ultralow-dose rituximab in neuromyelitis optica
spectrum disorder.
J Neuroimmunol. 2024;387:578285. PubMedAbstract available
LOTFI A, Abbasi M, Karami N, Arghavanfar H, et al Effects of treadmill training on myelin proteomic markers and cerebellum
morphology in a rat model of cuprizone-induced toxic demyelination.
J Neuroimmunol. 2024;387:578286. PubMedAbstract available
SERAFINI B, Benincasa L, Rosicarelli B, Aloisi F, et al EBV infected cells in the multiple sclerosis brain express PD-L1: How the virus
and its niche may escape immune surveillance.
J Neuroimmunol. 2024;389:578314. PubMedAbstract available
FRID K, Usmann A, Markovits-Pachter T, Binyamin O, et al Granagard administration prolongs the survival of human mesenchymal stem cells
transplanted into a mouse model of multiple sclerosis.
J Neuroimmunol. 2024;389:578313. PubMedAbstract available
LI X, Chen JJ, Hur M, Paton GR, et al Papillitis associated with IgLON5 autoimmunity: A novel clinical phenotype.
J Neuroimmunol. 2024;388:578312. PubMedAbstract available
TIAN J, Liu X, Liang H, Shen Y, et al Expression of lymphocyte activation gene-3 on CD4(+)T cells is regulated by
cytokine interleukin-18 in myasthenia gravis.
J Neuroimmunol. 2024;388:578308. PubMedAbstract available
GALETTA K, Ham AS, Vishnevetsky A, Bhattacharyya S, et al Disease modifying therapy in the treatment of tumefactive multiple sclerosis: A
retrospective cohort study.
J Neuroimmunol. 2024;388:578299. PubMedAbstract available
January 2024
THAKOLWIBOON S, Linnoila J, Pittock SJ, Dubey D, et al Cerebellar leptomeningeal enhancement: An imaging finding of rapidly progressive
Purkinje cell cytoplasmic autoantibody type 1 paraneoplastic cerebellar syndrome.
J Neuroimmunol. 2024;387:578293. PubMedAbstract available
WADI L, Mandge V Electroconvulsive therapy for catatonia in anti-NMDA receptor encephalitis: A
case series.
J Neuroimmunol. 2024;386:578271. PubMedAbstract available
CERNE D, Losa M, Mattioli P, Lechiara A, et al Incident anti-LGI1 autoimmune encephalitis during dementia with Lewy bodies: when
Occam razor is a double-edged sword.
J Neuroimmunol. 2024;387:578291. PubMedAbstract available
PETERSEN-CHERUBINI CL, Liu Y, Deffenbaugh JL, Murphy SP, et al Dysregulated autotaxin expression by T cells in multiple sclerosis.
J Neuroimmunol. 2024;387:578282. PubMedAbstract available
FUJIMORI J, Nakashima I Early-stage volume losses in the corpus callosum and thalamus predict the
progression of brain atrophy in patients with multiple sclerosis.
J Neuroimmunol. 2024;387:578280. PubMedAbstract available
December 2023
BAEVA ME, Tottenham I, Koch M, Camara-Lemarroy C, et al Biomarkers of disability worsening in inactive primary progressive multiple
sclerosis.
J Neuroimmunol. 2023;387:578268. PubMedAbstract available
STAVROGIANNI K, Kitsos DK, Giannopapas V, Chasiotis AK, et al Neuropsychological profiles comparison between Multiple Sclerosis patients and
Multiple Sclerosis patients with overlapping features of Systemic Lupus
Erythematosus.
J Neuroimmunol. 2023;387:578270. PubMedAbstract available
LI HY, Xia M, Song M, Xie Y, et al Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and
initial short-term glucocorticoids efficacy in myasthenia gravis patients.
J Neuroimmunol. 2023;387:578269. PubMedAbstract available
HU B, Dang G, Chen S, Li S, et al Neuromyelitis optica spectrum disorder mimicking stroke: A case report and
literature review.
J Neuroimmunol. 2023;385:578223. PubMedAbstract available
MIYAZAWA R, Fujimori J, Atobe Y, Nakashima I, et al CSF CXCL13 is elevated in patients with CIDP and may reflect higher disease
activity.
J Neuroimmunol. 2023;385:578238. PubMedAbstract available
TESFAGIORGIS Y, Kemal EA, Craig HC, Parham KA, et al Systemic administration of anti-CD20 indirectly reduces B cells in the inflamed
meninges in a chronic model of central nervous system autoimmunity.
J Neuroimmunol. 2023 Dec 15:578267. doi: 10.1016/j.jneuroim.2023.578267. PubMedAbstract available
November 2023
CHEN Y, Wan W, Yao X, Guan Y, et al Drug-drug interaction between paxlovid and tacrolimus in a patient with
myasthenia gravis and SARS-CoV-2 infection.
J Neuroimmunol. 2023;385:578245. PubMedAbstract available
LOWE MC, Money KM, Matthews E, Pastula DM, et al case of autoimmune GFAP astrocytopathy with eosinophils in the cerebrospinal
fluid.
J Neuroimmunol. 2023;385:578249. PubMedAbstract available
CAO B, Li Q, Xiong L, Ruan H, et al Cerebrospinal fluid uric acid levels associated with disease severity in patients
with anti-N-methyl-d-aspartate receptor encephalitis.
J Neuroimmunol. 2023;384:578221. PubMedAbstract available
LI Y, Liu Y, Zhao W, An X, et al Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis
optica spectrum disorder.
J Neuroimmunol. 2023;384:578218. PubMedAbstract available
YASUDA M, Uzawa A, Kuwabara S, Suzuki S, et al Clinical features and outcomes of patients with muscle-specific kinase
antibody-positive myasthenia gravis in Japan.
J Neuroimmunol. 2023;385:578241. PubMedAbstract available
FARAJI J, Bettenson D, Yong VW, Metz GAS, et al Early life stress aggravates disease pathogenesis in mice with experimental
autoimmune encephalomyelitis: Support for a two-hit hypothesis of multiple
sclerosis etiology.
J Neuroimmunol. 2023;385:578240. PubMedAbstract available
October 2023
LEAL RATO M, Santos M, de Sa J, Ferreira J, et al Comorbid autoimmune disorders in people with multiple sclerosis: A retrospective
cohort study.
J Neuroimmunol. 2023;385:578226. PubMedAbstract available
MOORE L, Munir A, Bae S, Miller J, et al Transverse myelitis associated with Mpox infection.
J Neuroimmunol. 2023;383:578190. PubMedAbstract available
KORAL G, Ulusoy C, Cossins J, Lazaridis K, et al Silencing of FCRLB by shRNA ameliorates MuSK-induced EAMG in mice.
J Neuroimmunol. 2023;383:578195. PubMedAbstract available
RASHED HR, Niu Z, Dyck PJ, Dyck PJB, et al Nerve transcriptomes in autoimmune and genetic demyelinating neuropathies:
Pathogenic pathway assessment of nerve demyelination.
J Neuroimmunol. 2023;384:578220. PubMedAbstract available
KIM KW, Ljunggren-Rose A, Matta P, Toki S, et al Inhibition of SUMOylation promotes remyelination and reduces IL-17 mediated
autoimmune inflammation: Novel approach toward treatment of inflammatory CNS
demyelinating disease.
J Neuroimmunol. 2023;384:578219. PubMedAbstract available
September 2023
DOMINGUEZ L, McKeon A, Tobin WO, Lopez-Chiriboga S, et al Long term outcomes in patients with anti-DPPX autoimmunity.
J Neuroimmunol. 2023;384:578214. PubMedAbstract available
HOLM-YILDIZ S, Dysgaard T, Krag T, Pedersen BS, et al Humoral immune response to COVID-19 vaccine in patients with myasthenia gravis.
J Neuroimmunol. 2023;384:578215. PubMedAbstract available
YASUDA M, Uzawa A, Ozawa Y, Kojima Y, et al Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase
antibodies.
J Neuroimmunol. 2023;384:578205. PubMedAbstract available
CHENG X, Li Y, Wang Y, Sun Y, et al Impact of blood-brain barrier disruption on clinical features and treatment
response in patients with newly diagnosed autoimmune encephalitis.
J Neuroimmunol. 2023;383:578203. PubMedAbstract available
ROSHAN HM, Valadan R, Hosseini SA, Ajami A, et al Specific antibodies to EBNA1 epitopes as risk factors for multiple sclerosis, a
systematic review.
J Neuroimmunol. 2023;383:578202. PubMedAbstract available
CHHABRA S, Mehan S, Khan Z, Gupta GD, et al Matrine mediated neuroprotective potential in experimental multiple sclerosis:
Evidence from CSF, blood markers, brain samples and in-silico investigations.
J Neuroimmunol. 2023;384:578200. PubMedAbstract available
MICHAEL MR, Wieske L, Koel-Simmelink MJ, van Schaik IN, et al Serum B-cell activating factor is not a potential biomarker for disease activity
in chronic inflammatory demyelinating polyneuropathy.
J Neuroimmunol. 2023;382:578169. PubMedAbstract available
YAMAHARA N, Yoshikura N, Takekoshi A, Kimura A, et al Anti-N-methyl-d-aspartate receptor encephalitis preceded by meningitis lasting up
to 60 days.
J Neuroimmunol. 2023;382:578173. PubMedAbstract available
NI J, Liu X, Zhang R, Wang H, et al Systemic administration of Shikonin ameliorates cognitive impairment and neuron
damage in NPSLE mice.
J Neuroimmunol. 2023;382:578166. PubMedAbstract available
HUANG Z, Liu Y, An X, Zhang C, et al Rituximab induces a transient fluctuation of peripheral and follicular helper T
cells in neuromyelitis optica spectrum disorder.
J Neuroimmunol. 2023;382:578167. PubMedAbstract available
ERLEBACH R, Brandi G Effect and timing of operative treatment for teratoma associated
N-Methyl-d-Aspartate receptor-antibody encephalitis: A systematic review with
meta-analysis.
J Neuroimmunol. 2023;382:578153. PubMedAbstract available
GELIBTER S, Pirro F, Saraceno L, Susani E, et al Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica
Spectrum Disorder during anti-CD20 treatment: A single-center experience.
J Neuroimmunol. 2023;383:578199. PubMedAbstract available
PERDAENS O, van Pesch V MicroRNAs are dysregulated in peripheral blood mononuclear cells in multiple
sclerosis and correlate with T cell mediators.
J Neuroimmunol. 2023;386:578196. PubMedAbstract available
August 2023
KHAN E, Kagzi Y, Elkhooly M, Surpur S, et al Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A
systematic review and meta-analysis.
J Neuroimmunol. 2023;383:578178. PubMedAbstract available
TERRIM S, Silva GD, de Sa E Benevides Falcao FC, Dos Reis Pereira C, et al Real-world application of the 2022 diagnostic criteria for first-ever episode of
optic neuritis.
J Neuroimmunol. 2023;381:578140. PubMedAbstract available